Uganda begins largest trial of experimental Ebola vaccine

Researchers in Uganda are launching the largest-ever trial of an experimental Ebola vaccine that is expected to be deployed in neighboring Congo, where a deadly outbreak has killed over 1,800 people. The trial of the Janssen Pharmaceuticals vaccine involves up to 800 people and is supported by Doctors without Borders and the London School of Hygiene and Tropical Medicine. Pontiano […]

Read more

Psychotherapy should be first-line treatment for depression in young people, trial finds

Young people seeking support for depression should be offered psychotherapy as the first line of treatment, a clinical trial by researchers at Orygen, the National Centre of Excellence in Youth Mental Health, has found. Associate Professor Christopher Davey, head of mood disorder research at Orygen, said the clinical trial results emphasised the importance of a multi-faceted approach to treating depression […]

Read more

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

Taking a daily vitamin D supplement does not prevent type 2 diabetes in adults at high risk, according to results from a study funded by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health. The Vitamin D and Type 2 Diabetes (D2d) study enrolled 2,423 adults and was conducted at 22 sites […]

Read more

Sodium intake associated with increased lightheadedness in context of DASH-sodium trial

Lightheadedness with standing, otherwise known as postural lightheadedness, results from a gravitational drop in blood pressure and is common among adults. While mild in many adults, it has been cited as an important contributing factor in some harmful clinical events, such as falls. As a result, greater sodium intake is widely viewed as an intervention for preventing lightheadedness when moving […]

Read more

argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia

Breda, the Netherlands / Ghent, Belgium – December 03, 2018 — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced  that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)  and […]

Read more

Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine

BRISBANE, Calif.–(BUSINESS WIRE)–Nov. 18, 2018– Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the New England Journal of Medicine (NEJM) has published the full results of the landmark phase 3 PALISADE clinical trial of AR101, Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy. PALISADE is the largest […]

Read more